#USA #New York #Securities Fraud #Rosen Law Firm #Unicycive

Unicycive Therapeutics Investors Can Lead in Class Action Lawsuit

In a significant legal development, investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) are invited to join a class action lawsuit initiated by the Rosen Law Firm, a renowned global firm focusing on investor rights. This lawsuit pertains to allegations of securities fraud that occurred between December 29, 2025, and June 29, 2026, marking the period when affected shareholders purchased Unicycive's securities.

Key Highlights of the Class Action

The Rosen Law Firm has taken the lead in this case to represent investors who feel misled by misleading statements made by Unicycive throughout the defined Class Period. As specified, if you wish to be recognized as the lead plaintiff in this case, you must submit your application by November 2, 2026. A lead plaintiff’s role is crucial as they represent the collective interests of all involved shareholders and guide the litigation process.

Why Join the Lawsuit?

Purchasing Unicycive securities may entitle you to compensation without incurring out-of-pocket costs, thanks to the firm's contingency fee structure. This means that if the case does not succeed, you will not be liable for legal fees.

For those wishing to participate, the firm provides straightforward instructions. Interested parties can join by visiting their website at rosenlegal.com or by contacting Phillip Kim, Esq. at 866-767-3653 or [email protected].

The Nature of Allegations

The lawsuit revolves around several critical points regarding Unicycive’s operational practices. Key allegations suggest that during the Class Period:
1. Unicycive failed to inspect its third-party manufacturing facilities or to ensure compliance with FDA regulations.
2. Due to this failure, Unicycive was unable to confidently assert that previous deficiencies reported by the FDA had been adequately resolved.
3. There was an undisclosed risk that regulatory approval for Unicycive’s oxylanthanum carbonate (OLC) could be delayed, impacting potential returns for investors.
4. Accordingly, the company’s optimistic public statements regarding its business performance lacked a factual basis, misguiding investors.

The lawsuit argues that as the truth of these operational failures came to light, investors experienced significant financial losses due to the drop in stock prices.

How Rosen Law Firm Stands Out

Rosen Law Firm emphasizes the importance of engaging legal representation that has established credibility and success in similar cases. The firm has gained recognition for achieving substantial settlements on behalf of investors, including high-profile cases against major corporations. In 2019 alone, they secured over $438 million for investors affected by securities fraud. Their consistent track record positions them as a trusted advocate for investor rights.

Important Considerations

It's crucial to note that as of now, no class has been officially certified. This entails that until such certification, potential plaintiffs are not directly represented unless they choose to retain their own counsel. Investors wishing to remain passive participants in the class action may do so without affecting their potential recovery from any future settlements.

In conclusion, the opportunity for Unicycive investors to join this class action represents a critical moment to seek justice for alleged fraudulent activities that have impacted their investments. Stakeholders are encouraged to act promptly and stay informed by following the developments via the Rosen Law Firm’s social media platforms, including LinkedIn and Twitter.

To learn more about the case and the process for joining the class action, don’t hesitate to visit Rosen Law Firm or contact their offices directly for detailed information.